tbuckley/cabot-search huggingface dataset:
PTU-077 Increased Long-Term Cancer Risk in Autoimmune Hepatitis (AIH): Relation to Immunosuppressive Drug Treatment
Authors: BS Hoeroldt, D Gleeson, K Shephard, N Farquarson, E MacFarlane, M Karajeh, J Poole
Journal: Gut (2016)

<h3>Introduction</h3> &nbsp; <h3>Background</h3> Increased rates of hepatocellular (HCC) and recently, of extra-hepatic cancer have been reported in Autoimmune Hepatitis (AIH). Increased cancer rates in inflammatory bowel disease and following organ transplant have been linked to immunosuppressive (IS) drug therapy; this association has not been assessed in AIH. <b> Aim</b>. Evaluation relationship of cancer risk to non-steroid IS therapy in AIH <h3>Methods</h3> 241 patients (197 F, age at diagnosis (median (range) 56 (2.5–87 yr), presenting 1971–2007 with AIH (1999 International Group criteria) and followed for ≥6 months. Cancers (ICD-10 code starting with C) were captured by clinical record review and individually linked to data from the English National Cancer Registry. In cases of discrepancy, records were re-checked and a consensus decision made. Patients were censored at death, liver transplant, changed diagnosis to PBC, cessation of follow up, or on 1/1/2014. We excluded cancers diagnosed before or within 6 months of AIH diagnosis or &gt;30 days after follow-up ceased. Standardised incidence ratios (SIR; first cancer only) were calculated, relative to age-gender adjusted UK population rates. For non-melanoma skin cancer (NMSC), we considered only the years 2000–13, as there was under-reporting of NMSC to the registry prior to this. We estimated (pre-cancer) duration and cumulative dose of azathioprine (received by 208 patients) and total duration of all (non-steroid only) IS drug therapy. <h3>Results</h3> Follow up was 12 (0.5–43 yr): total 3134 patient-years. There was development of (a) HCC in 10 patients (all with cirrhosis): SIR (95% CI) 41 (20–75); (b) lympho-proliferative cancer in 6 patients: SIR 2.94 (1.08–6.4: (c) ≥1 NMSC in 15 patients (2000–13): SIR 2.95 (1.65–4.87). SIR for all other extra-hepatic cancers remained above unity: 1.51 (1.07–2.07). Using a competing risks regression model, age-adjusted all-cancer risk was associated with duration (Hazard ratio (HR) 1.10 (1.01–1.20) and with cumulative dose (HR 1.07 (1.00–1.15) of azathioprine and with total duration of non-steroid IS therapy (HR 1.07 (1.01–1.14). Compared to those receiving non-steroid IS for &lt;0.25 yr, age-adjusted all-cancer HR was 2.54 (1.13–5.72) and 8.71 (3.55–21.4) in those receiving IS for 0.25–10 yr and for &gt;10 yr respectively. <h3>Conclusion</h3> Patients with AIH have increased risk of hepatic and extra-hepatic cancer, including lymphoproliferative and NMSC. This risk is associated with duration of non-steroid IS drug therapy. <h3>Disclosure of Interest</h3> None Declared
OP0216 Safety of Tocilizumab, Interleukin-1 Inhibitors and Etanercept in 262 Systemic Juvenile Idiopathic Arthritis Patients: Table 1
Authors: G. Horneff, A.C. Schultz, A. Hospach, G. Ganser, I. Foeldvari, A. Thon, R. Trauzeddel, F. Weller, K. Minden, J.P. Haas
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Since the approval of first biologics for treatment of JIA, surveillance in Germany is monitored prospectively by the BIKER registry. <h3>Objectives</h3> To evaluate the safety of Tocilizumab (TOC), IL-1 inhibitors (Anakinra &amp; Canakinumab) and Etanercept (ETA). <h3>Methods</h3> Safety assessments were based on adverse events reports. <h3>Results</h3> 205 sJIA pts received 269 treatment courses with biologics (TOC 71, Anakina 36, Canakinumab 19, ETA 143 and 57 pts. received MTX only. Median age was lower In the MTX cohort (4.8y) than with ETA (8.2); TOC (9.6); IL-1i (8.2) as was the disease duration. ETA was started in 80% of pts before 2008 while in the TOC cohort all pts and in the IL-1i cohort 74% started therapy after 2008. Pre-treatment consisted of systemic steroids in 75% starting MTX and in all patients starting biologics. Initial concomitant treatment with systemic steroids was significantly less frequent with TOC (44%, p&lt;0,001) and IL-1i (44%, p&lt;0.001) compared to 83% with ETA and 82 in MTX cohort. There were 30 adverse events (AE) in the MTX cohort, 71 in the ETA, 118 in the TOC and 81 in the IL-1i cohort. Rate of AE (per patient-year) was significantly higher in the TOC (RR 4.64; p&lt;0.0001) and IL-1i-group (RR 3.04; p&lt;0.01) (Table) and serious AE were also more frequent upon TOC (RR 5.5; p&lt;0.01) and IL1i (6.39; p&lt;0.01) but not upon ETA compared to the MTX cohort. There were 13 reports about Macrophage activation syndrome. Rates were not different. Of 125 infections, 13 were reported as serious. The infection rate was significantly higher in the TOC cohort (RR 4.3; p&lt;0.001)and IL-1i cohort (RR 2.93; p&lt;0.001) and significantly lower with ETA (RR 0.39; p&lt;0.01) than in the MTX cohort. Hodgkin9s lymphoma, Crohn9s disease and demyelination occurred once in the ETA cohort, one case with a depression with suicidal thoughts occurred with IL-1i. Intolerance led to discontinuation of ETA in 3.5%, TOC in 8.3% and IL-1i in 2%. 2 pts died (septic shock &amp; MAS) not related to biologics. <h3>Conclusions</h3> Higher rates of safety signals, especially infections were noted upon treatment with TOC and IL-1i. Beside infections, disease reactivation and MAS, further adverse events were rare and overall tolerability was acceptable. However, steroids were markedly spared upon IL6- and Il-1 inhibitors. <h3>Disclosure of Interest</h3> G. Horneff Grant/research support from: Abbvie, Roche, Chugai, Pfizer, A. Schultz: None declared, A. Hospach: None declared, G. Ganser: None declared, I. Foeldvari: None declared, A. Thon: None declared, R. Trauzeddel: None declared, F. Weller: None declared, K. Minden: None declared, J. Haas: None declared
Role of Etoposide in Combination with All-Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation
Authors: Marie-Luise Hütter, Konstanze Döhner, Ingo G.H. Schmidt-Wolf, Francisco Del Valle, Björn Heydrich, Wolfgang Heit, Walter Fiedler, Michael Pfreundschuh, Gudrun Russ, Martin Bentz, Aruna Raghavachar, Detlef Haase, Wolfram Brugger, Katharina Götze, Silja Groner, Hartmut Döhner, Richard Schlenk
Journal: Blood (2008)
AB0920 Any Predictive Factors of Therapeutic Response in Infectious Spondylitis?
Authors: I. Gharsallah, R. Dhahri, N. Boussetta, R. Abid, L. Metoui, F. Laajili
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The aim of the present work was to describe predictive factors of good or bad outcome Infectious Spondylodiscitis according to the experience of an internal medicine department in Tunisia. <h3>Methods</h3> Patients with SDI either confirmed or presumed and hospitalized in the internal medicine department of The Principle Military Hospital Of Tunis, Tunisia have been included in the Study. <h3>Results</h3> Fourty-four patients met the inclusion criteria. They have been gathered over 20 years-period. They were 24 men and 20 women with an average age at 52.5 years. The diagnosis was a Tuberculous Spondylodiscitis in 22 cases (50%): among them 10 patients had a concomitant extra spinal TB. The diagnostic delay was 231 days for TB SDI and 40.5 days for SDP. Length of hospital stay was 48.6 days (6–225 days): with a mean of 48.9 days in SDT and 45.3 days in SDP. Regular monitoring was observed in 38 patients (17 SDP, SDT 21) with an average duration of 20 months (5–48 months). Three were lost views and three died. Evolution was considered positive if there was a clinical and biological improvement and no recurrence or death. The analytical study objectified that existence of a immunosuppression, a longer diagnosis period, or hospitalization period and the follow-up duration were associated with a longer duration of treatment (p=0.038, p&lt;0.001). The absence of orthopedic complications initially or during the evolution and treatment duration were the only factors associated with good favorable change (p&lt;0.001, p=0.004), the existence of bacteriological evidence of multifocal involvement, the presence of epidural or spinal compression showed no significant association. <h3>Conclusions</h3> Earlier treatment with effective duration and follow up are predictive factors of favorable outcome in SDI either due to TB or regular germs. <h3>Disclosure of Interest</h3> None declared
Engineering of CD19-CAR T Cells from Non-Hodgkin Lymphoma Patients in a Closed System in Combination with Retronectin/OKT3 Stimulation
Authors: Hideto Chono, Kenichi Tahara, Ikuei Nukaya, Junichi Mineno, Eisuke Uehara, Tomonori Tsukahara, Ken Ohmine, Keiya Ozawa, Kazutoh Takesako
Journal: Blood (2014)
A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431
Authors: Michael A. Pulsipher, Bryan Langholz, Donna A. Wall, Kirk R. Schultz, Nancy Bunin, William L. Carroll, Elizabeth A. Raetz, Sharon Gardner, Julie M. Gastier-Foster, Denise Howrie, Rakesh Goyal, Douglas James, Michael J. Borowitz, Yvonne Jean Barnes, Shivanand R. Patil, David T Teachey, Candace Taylor, Stephan A Grupp
Journal: Blood (2011)
Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study
Authors: Stephan Stilgenbauer, Barbara F. Eichhorst, Johannes Schetelig, Steven Coutre, John F. Seymour, Talha Munir, Soham D. Puvvada, Clemens-Martin Wendtner, Andrew W. Roberts, Wojciech Jurczak, Stephen Mulligan, Sebastian Boettcher, Mehrdad Mobasher, Ming Zhu, Brenda Chyla, Maria Verdugo, Sari Heitner Enschede, Elisa Cerri, Rod A. Humerickhouse, Gary Gordon, Michael Hallek, William Wierda
Journal: Blood (2015)
Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET ‘negative’ after 3 Cycles of ABVD Chemotherapy.
Authors: Sally F Barrington, Michael J O’Doherty, Jane MacKewn, Paul Schleyer, Wendi Qian, Philippa Patrick, Timothy Illidge, Ruth Pettengell, Peter Hoskin, Barry Hancock, John Radford
Journal: Blood (2008)
FRI0064 Hyperglycemia Is A Pejorative Prognostic Factor of Clinical Outcome and Radiographic Progression in Early Rheumatoid Arthritis: Results of The ESPOIR Cohort
Authors: C.I. Daien, J. Sellam, N. Rincheval, B. Fautrel, A. Saraux, J. Morel, F. Berenbaum, J.-P. Daurès, B. Combe
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Diabetes was found to be increased in patients with rheumatoid arthritis (RA). <h3>Objectives</h3> The objective of this study was to evaluate the impact of hyperglycemia and diabetes on clinical activity and radiographic progression within the first 3 years in patients with early RA. <h3>Methods</h3> Patients of the ESPOIR cohort with early RA meeting the ACR/EULAR 2010 criteria and with data available for fasting blood sugar at baseline were analyzed. Glycemic status was analyzed with 2 different definitions: i) history of type I or II diabetes; ii) baseline blood sugar splitted into 3 categories: normal (&lt;5.55 mol/l), pre-diabetes (between 5.55 and 7 mmol/l) and diabetes (≥7 mmol/l). DAS28 and total Sharp score evolution during the first 3 years were compared between groups using multivariate mixed models. The multivariate models included the following variables: body mass index, age, gender, presence of rheumatoid factor and/or ACPA, glucorcorticoids. For DAS28 model, CRP was added in the model and for total Sharp score model, DAS28 and total Sharp were included. <h3>Results</h3> 26 patients were known to be diabetic and 619 patients were non-diabetic. At baseline, 479 patients had normal blood sugar; 96 had pre-diabetic levels and 26 had diabetic levels. These three groups initially differed on age, body mass index, presence of rheumatoid factor, and score DAS28 Sharp erosion. In multivariate analysis, DAS28 during the first three years were significantly higher in patients with hyperglycemia (p&lt;0.0001) and in patients with history of diabetes (p=0.05). Similarly, the structural progression was greater in patients with hyperglycemia inclusion with a dose-dependent effect (Figure 1A; p=0.006) and in patients with history of diabetes (Figure 1B; p=0.047). <h3>Conclusions</h3> In early RA, blood sugar level is an independent predictor of disease activity and structural progression at 3 years, with a dose-dependent effect. Beyond cardiovascular complications, the measurement of blood sugar in patients with early RA may also help to assess more precisely the prognosis of the disease. <h3>Disclosure of Interest</h3> None declared
THU0328 A Comprehensive Evaluation of Serum Autoantibodies in Primary Sjögren's Syndrome
Authors: C. Capaldo, G. Carvajal Alegria, B. Bendaoud, S. Jousse-Joulin, A. Saraux, J.-O. Pers, V. Devauchelle-Pensec, Y. Renaudineau
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Conventional antibodies are well described and studied in primary Sjögren syndrome, nevertheless patients can also present unconventional autoantibodies. <h3>Objectives</h3> The objective of this study was to investigate the prevalence of a large panel of conventional and unconventional autoantibodies (Ab) in a well-characterized population of patients with primary Sjögren9s syndrome (pSS). <h3>Methods</h3> Two hundred and twenty six pSS patients benefiting from a comprehensive clinical and radiological assessment were recruited. A new technique based on chemiluminescence (ISYS-IDS) was selected, in 44 patients, to assay 17 autoantigens including SSA/Ro (52+60 kDa), SSB/La, dsDNA, centromere, Sm, U1-snRNP, Scl70, Jo1, cardiolipin, β2-GPI, CCP2, PR3, MPO, GBM, transglutaminase (IgA), and deaminated gliadin (IgA&amp;IgG). If positive, the presence of Ab was validated by another technique. The study was completed by the search for anti-nuclear Ab (ANA) on HEp-2 cells and rheumatoid factors (RF) against human and rabbit IgG. <h3>Results</h3> Search for conventional Ab showed ANA (71.7% at 1:320), anti-SSA/Ro Ab (61.1%), anti-SSB/La Ab (31.0%, all anti-SSA+) and IgM RF (44.2%). The triple Ab association (ANA+SSA+RF) rather than the SSA/SSB association was associated with an earlier diagnosis, an active immunological profile (hypergammaglobulinemia, erythrocyte sedimentation rate) and a salivary gland involvement (lymphocyte infiltration, ultrasonography and enlargement). Three patients out of 44 (6.8%) had unintended Ab in current practice directed against centromere, Jo1, and dsDNA plus IgG deaminated gliadin Ab but without associated clinical signs. <h3>Conclusions</h3> The ability to combine a wide range of autoantibodies can lead to defining new subgroups of pSS patients for precise disease characterization, patient stratification and response prediction. <h3>Disclosure of Interest</h3> None declared
Critically ill patients demonstrate large interpersonal variation in intestinal microbiota dysregulation: a pilot study
Authors: Jacqueline M. Lankelma, Lonneke A. van Vught, Clara Belzer, Marcus J. Schultz, Tom van der Poll, Willem M. de Vos, W. Joost Wiersinga
Journal: Intensive Care Medicine (2016)

The intestinal microbiota has emerged as a virtual organ with essential functions in human physiology. Antibiotic-induced disruption of the microbiota in critically ill patients may have a negative influence on key energy resources and immunity. We set out to characterize the fecal microbiota composition in critically ill patients both with and without sepsis and to explore the use of microbiota-derived markers for clinical outcome measurements in this setting. In this prospective observational cohort study we analyzed the fecal microbiota of 34 patients admitted to the intensive care unit. Fifteen healthy subjects served as controls. The fecal microbiota was phylogenetically characterized by 16S rRNA gene sequencing, and associations with clinical outcome parameters were evaluated. A marked shift in fecal bacterial composition was seen in all septic and non-septic critically ill patients compared with controls, with extreme interindividual differences. In 13 of the 34 patients, a single bacterial genus made up >50% of the gut microbiota; in 4 patients this was even >75%. A significant decrease in bacterial diversity was observed in half of the patients. No associations were found between microbiota diversity, Firmicutes/Bacteroidetes ratio, or Gram-positive/Gram-negative ratio and outcome measurements such as complications and survival. We observed highly heterogeneous patterns of intestinal microbiota in both septic and non-septic critically ill patients. Nevertheless, some general patterns were observed, including disappearance of bacterial genera with important functions in host metabolism. More detailed knowledge of the short- and long-term health consequences of these major shifts in intestinal bacterial communities is needed.
SAT0291 Intima Media Thickness and Atherosclerotic Plaques as Markers of Subclinical Atherosclerosis and Cardiovascular Manifestation in Sle Patients
Authors: A. Smržová, M. Schubertová, J. Vymětal, M. Skácelová, A. Petráčková, E. Kriegova, Z. Heřmanová, F. Mrázek, P. Horák
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Cardiovascular diseases are the main cause of morbidity and mortality in SLE patients. Detection of risk factors can increase survival and improve quality of life. <h3>Objectives</h3> The aim of study was the detection of subclinical atherosclerosis measured by ultrasound evaluation of intima media thickness and its correlatation to PVW (pulse velocity wave), traditional risk factor, and clinical profile of the disease, autoantibodies and selected laboratory markers. <h3>Methods</h3> From March 2015 to January 2016 we examined 42 patients with SLE (5 men, 37 women) by ultrasound of carotic arteries. Traditional risk factors, clinical manifestation, immunological profile and disease activity scores (SELENA-SLEDAI 2K, SLICC) were collected. Cumulative dose of glucocorticosteroids and duration of disease was calculated. History of cardiovascular events was recorded. Statistical tests (descriptive statistic, Student t-test, Spearman test, ANOVA) were performed, p-value ≤0.05 was considered as significant. <h3>Results</h3> Pathological IMT was detected in 10 patients (23.8%). IMT correlated with cumulative dose of glucocorticoids, levels of anti ds DNA (p=0.05), low levels of C3 (p=0.03), positivity of LA and high LSR (p=0.007,p=0.05), low levels of GF and serum creatinine (p=0.03, p=0.04), anti La antibodies (p=0.009), leucopenia (p=0.007), haematological manifestation (p=0.04), dyslipidemia (p=0.03) and PVW (p=0.01). The presence of plaques correlated with BMI (p=0.05), cardiac failure (p=0.03), anti ds DNA (p=0.03), LA (p=0.003), low levels of HDL (p=0.005), hsCRP (p=0.05), PWV (p=0.04). If groups with or without pathological IMT were compared, there was difference in age (p≤0.001), smoking - packet-years (p=0.01), cardial failure (p=0.02), stroke and lupus CNS (p=0.02, resp. 0.003), cardiac manifestation (p=0.003) and hrCRP (p=0.02). There was no correlation in lipid profile. In this group 5 strokes, 5 cardiac failure, 2 myocardial infarction, 4 ischemic heart disease and 6 cardiac manifestation were present. <h3>Conclusions</h3> IMT and detection of plaques are very important markers of subclinical atherosclerosis. They correlated with traditional risk factors and are good prognostic factor of cardiovascular and ischemic CNS manifestation. It is important to evaluated both IMT and plaques. The result of the study highlights the necessity of active screening of cardiac involvement in SLE patients. <h3>Acknowledgement</h3> Grant support: MZ CR VES15–28659A <h3>Disclosure of Interest</h3> None declared
Indirect Comparison to Assess the Relative Efficacy of Carfilzomib + Lenalidomide + Dexamethasone Versus Bortezomib + Thalidomide + Dexamethasone: A Matching Adjusted Indirect Comparison
Authors: Michael Rael, Agnes Benedict, Jack Ishak, Sarah Cadarette, Marco Campioni, Sumeet Panjabi
Journal: Blood (2015)
What now for Obamacare?
Authors: Douglas Kamerow
Journal: BMJ (2016)

Background:Periventricular haemorrhagic infarction (PVHI) is a complication of preterm birth that may lead to impairment and disability. Early diagnosis is possible by cranial ultrasonography (CUS). Extensive PVHI lesions can be graded using a scoring system that relates to outcome, based on CUS characteristics. Data on more subtle unilateral forms of PVHI are lacking.
  Objective:To refine PVHI classification by relating subtypes to affected veins and evaluate effects of these different anatomical subtypes on neurological outcome.
  Methods:We retrospectively analyzed images and neurological outcome of 20 preterm infants with unilateral PVHI. Based on affected veins we classified PVHI into six subtypes. Sonographic templates of infarct types are provided in coronal and parasagittal plane. Standardized neurological examinations were done (according to Amiel-Tison and Touwen9s examinations) and children were classified as: normal, mildly or definitely abnormal. The outcome was based on the most recent neurological examination, at a corrected age of 1 (n=7), 2 (n=5), 3 (n=5) or 5 (n=3) years of age.
  Results:PVHI classification of the 20 patients was as follows:  temporal (n=3), pure caudate (n=3), anterior terminal (n=6), complete terminal (n=3), extensive (n=4), other (n=1). With one exception, only PVHI patients showing the latter three subtypes had developed severe spastic contralesional hemiplegia.   Conclusions:The classification developed for PVHI correlates with neurological outcome. This refinement can help clinicians in predicting neurological outcome at an early stage, with a subsequent targeted rehabilitation schedule already early in life.
Influence of Umbilical Cord Blood-Derived Endothelial Precursor Cells on a Human Umbilical Vein Endothelial Cell Co-Culture In Vitro Angiogenesis Assay.
Authors: Nicholas J. Greco, Brandon Eilertson, Jason J. Banks, Paul Scheid, Marcie Finney, Shyam Bhakta, Vincent J. Pompili, Mary J. Laughlin
Journal: Blood (2005)
Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study
Authors: Caryn S Ross-Innes, Hamza Chettouh, Achilleas Achilleos, Nuria Galeano-Dalmau, Irene Debiram-Beecham, Shona MacRae, Petros Fessas, Elaine Walker, Sibu Varghese, Theodore Evan, Pierre S Lao-Sirieix, Maria O'Donovan, Shalini Malhotra, Marco Novelli, Babett Disep, Phillip V Kaye, Laurence B Lovat, Rehan Haidry, Michael Griffin, Krish Ragunath, Pradeep Bhandari, Adam Haycock, Danielle Morris, Stephen Attwood, Anjan Dhar, Colin Rees, Matt D Rutter, Richard Ostler, Benoit Aigret, Peter D Sasieni, Rebecca C Fitzgerald
Journal: The Lancet. Gastroenterology & hepatology (2016)
Successful recanalization of complete anastomotic stricture using colorectal endoscopic ultrasound-guided rendezvous thus allowing stoma reversal: two cases
Authors: Laurent Poincloux, Denis Pezet, Olivier Rouquette
Journal: Endoscopy (2016)

Anastomotic stricture frequently occurs with colorectal surgery [1]. Endoscopic dilation or stenting may be used to avoid surgical reintervention [2]. If this fails, endoscopic ultrasound (EUS)-guided stent placement has been proposed [3]. We report two cases of successful EUS-guided colorectal stricture recanalization made possible by two methods of filling the colon with water ([Fig. 1]; [Video 1]).
Reconstitution of the T Cell Repertoire Following Treatment with Alemtuzumab in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL).
Authors: Mohammad R. Rezvany, Mahmood J. Tehrani, Claes Karlsson, Jeanette Lundin, Hodjattallah Rabbani, Håkan Mellstedt, Anders Österborg
Journal: Blood (2005)